a-D2PV

α-D2PV, also known as α-pyrrolidino-2-phenylacetophenone or diphenyl-2-pyrrolidinyl ethanone, is an unusual synthetic cathinone-related stimulant. Unlike typical pyrovalerones, it has a second phenyl ring in place of the extended alkyl side chain. Its chemical identity has been confirmed in seized material, but direct pharmacological and clinical research remains sparse.

Chemistry and structure

α-D2PV is 1,2-diphenyl-2-(pyrrolidin-1-yl)ethan-1-one. It retains a ketone group and a pyrrolidine substituent, but the side-chain carbon is attached to a second phenyl ring. This makes it structurally unusual among pyrrolidino-cathinones and gives it some resemblance to diarylethylamine dissociatives, although it remains a distinct chemical entity.

The US FDA Substance Registration System lists α-D2PV under the name 1,2-diphenyl-2-(1-pyrrolidinyl)ethanone. A 2023 crystallographic report confirmed the structure in a seized powder that also contained myo-inositol as a diluent (Crystal structure and analytical profile of α-D2PV, 2023).

Pharmacology

There is no detailed receptor or transporter profile for α-D2PV. The UK Advisory Council on the Misuse of Drugs describes it as structurally related to diphenidine and notes that its unusual aryl substitution places it outside some generic definitions used for conventional cathinones. This structural relationship does not establish that α-D2PV has the same NMDA-receptor activity as diphenidine (ACMD, 2025).

Reported effects

The available descriptions are based on a small number of user reports rather than clinical studies. The ACMD review summarises reports of euphoria, stimulation, increased libido, vasoconstriction, anxiety and difficulty maintaining focus. These are anecdotal observations, which cannot establish a consistent or predictable pattern of effects.

Detection and toxicology

α-D2PV has appeared in drug-checking and forensic records. The ACMD review reports identifications in UK samples and notes that the substance was detected in a small number of submitted materials. A US National Drug Early Warning System briefing also recorded online discussion of α-D2PV as an emerging stimulant, but online mentions are not evidence of prevalence or clinical harm (NDEWS online monitoring alert, 2022).

No robust human case series has established its acute toxic range, metabolism, dependence potential or long-term effects. Analysis of the seized material confirms the compound’s identity, without establishing its clinical safety.

Research limitations

α-D2PV is a good example of why chemical resemblance alone can be misleading. Its pyrrolidine and ketone groups link it to cathinone chemistry, while the second phenyl ring makes it structurally different from conventional pyrovalerones. More direct receptor, transporter and clinical research is needed before its effects can be characterised confidently.

Related compounds

α-D2PV is related in broad structural terms to α-PVP, α-PCYP and Diphenidine, but its diaryl-substituted side chain distinguishes it from these compounds.